Bellicum Pharmaceuticals

Omrix Biopharmaceuticals

OMRIX develops and markets innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how. Acquired by Johnson & Johnson in 2008.

Select Venture Capital & Financial Partners

Catalyst Ventures Johnson & Johnson Development Corporation MPM Capital